RU2004127928A - Производные морфолинилмочевины для использования в лечении воспалительных заболеваний - Google Patents

Производные морфолинилмочевины для использования в лечении воспалительных заболеваний Download PDF

Info

Publication number
RU2004127928A
RU2004127928A RU2004127928/04A RU2004127928A RU2004127928A RU 2004127928 A RU2004127928 A RU 2004127928A RU 2004127928/04 A RU2004127928/04 A RU 2004127928/04A RU 2004127928 A RU2004127928 A RU 2004127928A RU 2004127928 A RU2004127928 A RU 2004127928A
Authority
RU
Russia
Prior art keywords
methyl
compound
formula
morpholin
dichlorobenzyl
Prior art date
Application number
RU2004127928/04A
Other languages
English (en)
Russian (ru)
Inventor
Рейчел Энн ЭНКЛИФФ (GB)
Рейчел Энн ЭНКЛИФФ
Кэролин Мэри КУК (GB)
Кэролин Мэри КУК
Колин Дейвид ЭЛДРЕД (GB)
Колин Дейвид Элдред
Пол Мартин ГОР (GB)
Пол Мартин Гор
Ли Эндрю ХАРРИСОН (GB)
Ли Эндрю ХАРРИСОН
Мартин Алистер ХЭЙЗ (GB)
Мартин Алистер ХЭЙЗ
Саймон Тинби ХОДЖСОН (GB)
Саймон Тинби Ходжсон
Данкан Брюс ДЖАДД (GB)
Данкан Брюс ДЖАДД
Сюзанн Элейн КИЛИНГ (GB)
Сюзанн Элейн Килинг
Кс о Кинг ЛЬЮЭЛЛ (GB)
Ксяо Кинг ЛЬЮЭЛЛ
Гейл МИЛЛЗ (GB)
Гейл МИЛЛЗ
Грэм Майкл РОБЕРТСОН (GB)
Грэм Майкл РОБЕРТСОН
Стивен СУОНСОН (GB)
Стивен СУОНСОН
Эндрю Джон УОКЕР (GB)
Эндрю Джон УОКЕР
Марк УИЛКИНСОН (GB)
Марк УИЛКИНСОН
Original Assignee
Глаксо Груп Лимитед (GB)
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207434A external-priority patent/GB0207434D0/en
Priority claimed from GB0301608A external-priority patent/GB0301608D0/en
Application filed by Глаксо Груп Лимитед (GB), Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед (GB)
Publication of RU2004127928A publication Critical patent/RU2004127928A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU2004127928/04A 2002-03-28 2003-03-27 Производные морфолинилмочевины для использования в лечении воспалительных заболеваний RU2004127928A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0207434.2 2002-03-28
GB0207434A GB0207434D0 (en) 2002-03-28 2002-03-28 Novel compounds
GB0301608A GB0301608D0 (en) 2003-01-24 2003-01-24 Novel compounds
GB0301608.6 2003-01-24

Publications (1)

Publication Number Publication Date
RU2004127928A true RU2004127928A (ru) 2005-06-27

Family

ID=28676494

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004127928/04A RU2004127928A (ru) 2002-03-28 2003-03-27 Производные морфолинилмочевины для использования в лечении воспалительных заболеваний

Country Status (23)

Country Link
US (1) US7622464B2 (enExample)
EP (1) EP1487828B1 (enExample)
JP (1) JP4465195B2 (enExample)
KR (1) KR20040093488A (enExample)
CN (1) CN1656092A (enExample)
AR (1) AR040403A1 (enExample)
AT (1) ATE413399T1 (enExample)
AU (1) AU2003226757A1 (enExample)
BR (1) BR0308780A (enExample)
CA (1) CA2480106A1 (enExample)
CY (1) CY1108652T1 (enExample)
DE (1) DE60324535D1 (enExample)
DK (1) DK1487828T3 (enExample)
ES (1) ES2315519T3 (enExample)
IL (1) IL164047A0 (enExample)
IS (1) IS7444A (enExample)
MX (1) MXPA04009459A (enExample)
NO (1) NO20044448L (enExample)
PT (1) PT1487828E (enExample)
RU (1) RU2004127928A (enExample)
SI (1) SI1487828T1 (enExample)
TW (1) TW200400035A (enExample)
WO (1) WO2003082861A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615878B1 (en) 2003-01-14 2012-04-04 Cytokinetics, Inc. Compounds, compositions and methods of treatment for heart failure
JP4943837B2 (ja) 2003-04-03 2012-05-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良インヒビター
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
KR101276136B1 (ko) 2004-06-17 2013-06-18 싸이토키네틱스, 인코포레이티드 화합물, 조성물 및 방법
ES2564167T3 (es) * 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
JP4970946B2 (ja) 2004-09-08 2012-07-11 田辺三菱製薬株式会社 モルホリン化合物
EP1814875A4 (en) 2004-10-20 2010-02-17 Univ California IMPROVED INHIBITORS OF SOLUBLE EPOXY HYDROLASE
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
WO2007070683A2 (en) 2005-12-15 2007-06-21 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP5178526B2 (ja) 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
ES2748599T3 (es) 2007-08-27 2020-03-17 Dart Neuroscience Cayman Ltd Compuestos terapéuticos de isoxazol
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RU2512293C1 (ru) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов
CN107362362B (zh) * 2017-07-20 2019-01-01 复旦大学 Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用
WO2022023496A2 (en) * 2020-07-29 2022-02-03 Universidade De Santiago De Compostela Functionalized isonitriles and products, preparation and uses thereof
CA3190593A1 (en) * 2020-08-03 2022-02-10 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
CN119330881A (zh) * 2024-09-06 2025-01-21 苏州汉德创宏生化科技有限公司 一种3-氨甲基-1-h吡唑的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851526A (en) 1987-09-04 1989-07-25 Schering A.G. 1-(4-Substituted phenyl)-1H-imidazoles compounds
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
JPH10501212A (ja) 1994-05-19 1998-02-03 メルク シヤープ エンド ドーム リミテツド 5−ht▲下1d▼−アルファ作働薬としてのインドール−3−イルアルキルのピペラジン、ピペリジンおよびテトラヒドロピリジン誘導体
CA2195443A1 (en) 1994-07-20 1996-02-01 Bernhard Kohl Piperazine thiopyridines for controlling helicobacter bacteria
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IT1293807B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
US6031097A (en) 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
WO1999021848A2 (en) 1997-10-27 1999-05-06 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
CN1325397A (zh) 1998-09-30 2001-12-05 纽罗根公司 2-哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
ES2527688T3 (es) 2000-09-29 2015-01-28 Glaxo Group Limited Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias
CZ20031194A3 (cs) 2000-09-29 2003-08-13 Glaxo Group Limited Deriváty močoviny

Also Published As

Publication number Publication date
WO2003082861A2 (en) 2003-10-09
IS7444A (is) 2004-09-13
AU2003226757A1 (en) 2003-10-13
US20060063765A1 (en) 2006-03-23
WO2003082861A3 (en) 2004-03-11
TW200400035A (en) 2004-01-01
KR20040093488A (ko) 2004-11-05
DK1487828T3 (da) 2009-02-02
AR040403A1 (es) 2005-04-06
SI1487828T1 (sl) 2009-04-30
PT1487828E (pt) 2009-01-06
ATE413399T1 (de) 2008-11-15
CA2480106A1 (en) 2003-10-09
JP4465195B2 (ja) 2010-05-19
EP1487828B1 (en) 2008-11-05
NO20044448L (no) 2004-10-26
JP2005526815A (ja) 2005-09-08
EP1487828A2 (en) 2004-12-22
MXPA04009459A (es) 2005-01-25
CN1656092A (zh) 2005-08-17
US7622464B2 (en) 2009-11-24
IL164047A0 (en) 2005-12-18
DE60324535D1 (de) 2008-12-18
BR0308780A (pt) 2004-12-28
ES2315519T3 (es) 2009-04-01
CY1108652T1 (el) 2014-08-13

Similar Documents

Publication Publication Date Title
RU2004127928A (ru) Производные морфолинилмочевины для использования в лечении воспалительных заболеваний
JP2005526815A5 (enExample)
CA2656915A1 (en) Human protein tyrosine phosphatase inhibitors and methods of use
AU2011205283B2 (en) Compounds and methods
RU2013120064A (ru) Композиции и способы лечения глазного отека, неоваскуляризации и связанных с ними заболеваний
JP2006513258A5 (enExample)
JP2010526106A5 (enExample)
RU2009109147A (ru) Органические соединения
JP2004537554A5 (enExample)
JP2006506340A5 (enExample)
JP2010533158A5 (enExample)
CA2396824A1 (en) Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
CA2466490A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2015517580A5 (enExample)
JP2015533157A5 (enExample)
JP2007516173A5 (enExample)
JP2009525984A5 (enExample)
RU2011133833A (ru) Способы лечения синдрома сосудистой утечки
JP2004534035A5 (enExample)
RU2007138978A (ru) Гетероциклическое соединение
CA2583159A1 (en) Compounds for nonsense suppression, and methods for their use
JP2016512488A5 (enExample)
JP2008501673A5 (enExample)
JP2008503497A5 (enExample)
JP2009544742A5 (enExample)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20060529